Monocytes and CD34+ progenitors; complex tumor lysates containing normal, tumor-associated/shared and tumor-specific/private antigens, or synthetic MHC class I-restricted peptides; injection into blood (i.v.), skin (s.c. or i.d.), or lymph nodes (i.n.); are all parameters playing unclear roles in any clinical responses seen (Figure 2). This evidence concerns the gene CD34 and neoplasm.